In terms of clinicopathological features of the tumors, one is estrogen receptor (ER) positive with both ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IBC); the other is ER-positive DCIS. Here, ESR1 is linked to ductal breast carcinoma in situ.